STAT+: In a step forward for immunotherapy, new Bristol Myers drug slows melanoma in study
An experimental immunotherapy developed by Bristol Myers Squibb prevented metastatic melanoma from worsening when added to the company’s approved treatment, Opdivo, the company said Wednesday.
The result is a step forward for immunotherapy, a field that has seen only halting progress since the development of medicines like Opdivo and Merck’s rival treatment, Keytruda.
